Clevexel Pharma has entered into an agreement with Dynamix Pharmaceuticals for the development of a dual mechanism SYK/JAK molecule in rheumatoid arthritis (RA). The orally active SYK/JAK product is part of Dynamix’ lead development program and offers a new mechanism of action. Oral administration is of great interest as current treatments are mainly only injectable. The companies aim to bring the RA project to a clinical proof-of-concept stage, with preclinical development planned for early 201...